Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription

Articles published in Lung Cancer

Retrieve available abstracts of 465 articles:
HTML format

Single Articles

    November 2022
  1. PASSARO A, Russo GL, Passiglia F, D'Arcangelo M, et al
    Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Lung Cancer. 2022;174:118-124.
    PubMed     Abstract available

  2. MAZIERES J, Iadeluca L, Shaw AT, Solomon BJ, et al
    Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
    Lung Cancer. 2022;174:146-156.
    PubMed     Abstract available

  3. DE GIGLIO A, Grandinetti V, Aprile M, Borelli G, et al
    Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience.
    Lung Cancer. 2022;174:91-96.
    PubMed     Abstract available

  4. AGUADO DE LA ROSA C, Cruz Castellanos P, Lazaro-Quintela M, Domine M, et al
    Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
    Lung Cancer. 2022;173:83-93.
    PubMed     Abstract available

  5. SANCHIS-BORJA M, Fallet V, Fabre E, Wislez M, et al
    Characterization of lung cancers in patients with BRCA germline variants: A multicenter series.
    Lung Cancer. 2022;173:67-70.
    PubMed     Abstract available

  6. SOOSMAN SK, Schenker MP, Mazzola E, Voligny E, et al
    Safety of image guided research biopsies in patients with thoracic malignancies.
    Lung Cancer. 2022;173:53-57.
    PubMed     Abstract available

  7. DISSELHORST MJ, Lubeck Y, van der Noort V, Quispel-Janssen J, et al
    Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Lung Cancer. 2022;173:49-52.
    PubMed     Abstract available

  8. WANG M, Huang H, Xu Z, Li Z, et al
    Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
    Lung Cancer. 2022;173:28-34.
    PubMed     Abstract available

  9. KAUMANNS A, Konig D, Hojski A, Cattaneo M, et al
    Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study.
    Lung Cancer. 2022;173:14-20.
    PubMed     Abstract available

  10. CHAN JSK, Tang P, Ng K, Dee EC, et al
    Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study.
    Lung Cancer. 2022;174:67-70.
    PubMed     Abstract available

    October 2022
  11. ISOMOTO K, Haratani K, Tsujikawa T, Makutani Y, et al
    Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Lung Cancer. 2022;174:71-82.
    PubMed     Abstract available

  12. PINHEIRO PS, Callahan KE, Medina HN, Koru-Sengul T, et al
    Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity.
    Lung Cancer. 2022;174:50-56.
    PubMed     Abstract available

  13. BHARDWAJ M, Schottker B, Holleczek B, Brenner H, et al
    Comparison of discrimination performance of 11 lung cancer risk models for predicting lung cancer in a prospective cohort of screening-age adults from Germany followed over 17 years.
    Lung Cancer. 2022;174:83-90.
    PubMed     Abstract available

  14. JUSTEAU G, Huchot E, Simonneau Y, Roa M, et al
    Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
    Lung Cancer. 2022;174:45-49.
    PubMed     Abstract available

  15. TAN KS, Hsu M, Adusumilli PS
    Pathologic node-negative lung cancer: Adequacy of lymph node yield and a tool to assess the risk of occult nodal disease.
    Lung Cancer. 2022;174:60-66.
    PubMed     Abstract available

  16. SATO Y, Yamamoto H, Ikeda N, Konishi H, et al
    The impact of COVID-19 on thoracic surgical procedures in Japan: Analysis of data from the National Clinical Database.
    Lung Cancer. 2022;172:127-135.
    PubMed     Abstract available

  17. HUANG Y, Xu C, Sun Y, Wang W, et al
    Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.
    Lung Cancer. 2022;172:117-123.
    PubMed     Abstract available

  18. FELIP E, Smit EF, Molina-Vila MA, Dafni U, et al
    Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
    Lung Cancer. 2022;172:94-99.
    PubMed     Abstract available

  19. WANG C, Zhao K, Hu S, Dong W, et al
    Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
    Lung Cancer. 2022;172:86-93.
    PubMed     Abstract available

  20. LIU T, Guo L, Liu G, Dai Z, et al
    Identification of necroptosis-related signature and tumor microenvironment infiltration characteristics in lung adenocarcinoma.
    Lung Cancer. 2022;172:75-85.
    PubMed     Abstract available

  21. LIN M, Lu Y, Yu Q, Chen Z, et al
    Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study.
    Lung Cancer. 2022;172:29-34.
    PubMed     Abstract available

  22. AKHAVE N, Zhang J, Bayley E, Frank M, et al
    Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
    Lung Cancer. 2022;172:19-28.
    PubMed     Abstract available

  23. LIU SY, Zhang JT, Zeng KH, Wu YL, et al
    Perioperative targeted therapy for oncogene-driven NSCLC.
    Lung Cancer. 2022;172:160-169.
    PubMed     Abstract available

  24. WANG Y, Yang X, Li NJ, Xue JX, et al
    Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment.
    Lung Cancer. 2022;174:1-13.
    PubMed     Abstract available

    September 2022
  25. BASSE C, Chabanol H, Bonte PE, Fromantin I, et al
    Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
    Lung Cancer. 2022;173:116-123.
    PubMed     Abstract available

  26. HERZOG BH, Waqar SN, Devarakonda S, Ward JP, et al
    Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors.
    Lung Cancer. 2022;173:101-106.
    PubMed     Abstract available

  27. DICKSON JL, Hall H, Horst C, Tisi S, et al
    Utilisation of primary care electronic patient records for identification and targeted invitation of individuals to a lung cancer screening programme.
    Lung Cancer. 2022;173:94-100.
    PubMed     Abstract available

  28. LIM GHT, Balbi KJ, Poskitt B, Bennett P, et al
    Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
    Lung Cancer. 2022;173:71-74.
    PubMed     Abstract available

  29. ATARI M, Imai K, Nanjo H, Wakamatsu Y, et al
    Rapid intraoperative Ki-67 immunohistochemistry for lung cancer using non-contact alternating current electric field mixing.
    Lung Cancer. 2022;173:75-82.
    PubMed     Abstract available

  30. ZHANG Y, Goto Y, Yagishita S, Shinno Y, et al
    Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer.
    Lung Cancer. 2022;173:107-115.
    PubMed     Abstract available

  31. SARA KURUVILLA M, Liu G, Syed I, Gwadry-Sridhar F, et al
    EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Lung Cancer. 2022;173:58-66.
    PubMed     Abstract available

  32. YU Y, Zheng J, Han Z, Cui H, et al
    Suggestions on "Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer".
    Lung Cancer. 2022 Sep 11. pii: S0169-5002(22)00620.

  33. ZHANG W, Deng P, Kong T, Zhang B, et al
    Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2).
    Lung Cancer. 2022;173:43-48.
    PubMed     Abstract available

  34. ERHUNMWUNSEE L, Wing SE, Zou X, Coogan P, et al
    Neighborhood disadvantage and lung cancer risk in a national cohort of never smoking Black women.
    Lung Cancer. 2022;173:21-27.
    PubMed     Abstract available

  35. OHUCHI M, Yagishita S, Jo H, Akagi K, et al
    Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.
    Lung Cancer. 2022;173:35-42.
    PubMed     Abstract available

  36. DE ROOIJ BH, van den Hurk C, Smaardijk V, Fernandez-Ortega P, et al
    Development of an updated, standardized, patient-centered outcome set for lung cancer.
    Lung Cancer. 2022;173:5-13.
    PubMed     Abstract available

  37. BRADLEY P, Bola BM, Balata H, Sharman A, et al
    Incidental findings in low dose CT lung cancer screening of high-risk smokers: Results from the Manchester lung Health Check pilot.
    Lung Cancer. 2022;173:1-4.
    PubMed     Abstract available

  38. BOKHARI AA, Lai WY, Le AT, Gabre JL, et al
    Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Lung Cancer. 2022;171:103-114.
    PubMed     Abstract available

  39. YAMBAYEV I, Sullivan TB, Rieger-Christ KM, Servais EL, et al
    Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy.
    Lung Cancer. 2022;171:82-89.
    PubMed     Abstract available

  40. ZHANG T, Goel A, Xu X, Wu Y, et al
    N-mytistoyltransferase 1 and 2 are potential tumor suppressors and novel targets of miR-182 in human non-small cell lung carcinomas.
    Lung Cancer. 2022;171:70-81.
    PubMed     Abstract available

  41. ZHANG L, Wang Z, Fang J, Yu Q, et al
    Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
    Lung Cancer. 2022;171:56-60.
    PubMed     Abstract available

  42. LAU SCM, Rabindranath M, Weiss J, Li JJN, et al
    PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
    Lung Cancer. 2022;171:42-46.
    PubMed     Abstract available

  43. CANNATARO VL, Kudalkar S, Dasari K, Gaffney SG, et al
    APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.
    Lung Cancer. 2022;171:34-41.
    PubMed     Abstract available

    August 2022
  44. ADDEO A, Rothschild SI, Holer L, Schneider M, et al
    Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
    Lung Cancer. 2022;172:154-159.
    PubMed     Abstract available

  45. SAGIE S, Maixner N, Stemmer A, Lobachov A, et al
    Real-world evidence for immunotherapy in the first line setting in small cell lung cancer.
    Lung Cancer. 2022;172:136-141.
    PubMed     Abstract available

  46. SENTANA-LLEDO D, Viray H, Piper-Vallillo AJ, Widick P, et al
    Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
    Lung Cancer. 2022;172:124-126.
    PubMed     Abstract available

  47. STAMATIS G, Leschber G, Schwarz B, Brintrup DL, et al
    Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm.
    Lung Cancer. 2022;172:108-116.
    PubMed     Abstract available

  48. XIONG L, Wei Y, Zhou X, Dai P, et al
    Development and validation of nomograms based on clinical characteristics and CT reports for the preoperative prediction of precise lymph node dissection in lung cancer.
    Lung Cancer. 2022;172:35-42.
    PubMed     Abstract available

  49. NAVANI N, Butler R, Ibrahimo S, Verma A, et al
    Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
    Lung Cancer. 2022;172:142-153.
    PubMed     Abstract available

  50. XU Y, Xin W, Yan C, Shi Y, et al
    Organoids in lung cancer: A teenager with infinite growth potential.
    Lung Cancer. 2022;172:100-107.
    PubMed     Abstract available

  51. MALAPELLE U, Pisapia P, Pepe F, Russo G, et al
    The evolving role of liquid biopsy in lung cancer.
    Lung Cancer. 2022;172:53-64.
    PubMed     Abstract available

  52. MA T, Wen T, Cheng X, Wang Y, et al
    Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
    Lung Cancer. 2022;172:43-52.
    PubMed     Abstract available

  53. GRIESINGER F, Perol M, Girard N, Durand-Zaleski I, et al
    Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
    Lung Cancer. 2022;172:65-74.
    PubMed     Abstract available

  54. LIN YA, Hong YT, Lin XJ, Lin JL, et al
    Barriers and facilitators to uptake of lung cancer screening: A mixed methods systematic review.
    Lung Cancer. 2022;172:9-18.
    PubMed     Abstract available

  55. RODRIGUEZ ALVAREZ AA, Yuming S, Kothari J, Digumarthy SR, et al
    Sex disparities in lung cancer survival rates based on screening status.
    Lung Cancer. 2022;171:115-120.
    PubMed     Abstract available

  56. KANG TM, Hardcastle N, Singh AK, Slotman BJ, et al
    Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung.
    Lung Cancer. 2022;170:185-193.
    PubMed     Abstract available

  57. AHN B, Yoon S, Kim D, Chun SM, et al
    Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma.
    Lung Cancer. 2022;170:176-184.
    PubMed     Abstract available

  58. LIU M, Xia S, Zhang X, Zhang B, et al
    Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC.
    Lung Cancer. 2022;170:148-155.
    PubMed     Abstract available

  59. ZWIERENGA F, van Veggel B, Hendriks LEL, Hiltermann TJN, et al
    High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
    Lung Cancer. 2022;170:133-140.
    PubMed     Abstract available

  60. JURMEISTER P, Leitheiser M, Wolkenstein P, Klauschen F, et al
    DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas.
    Lung Cancer. 2022;170:105-113.
    PubMed     Abstract available

  61. QIN BD, Jiao XD, Wang Y, Wu Y, et al
    Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC.
    Lung Cancer. 2022;170:91-97.
    PubMed     Abstract available

  62. KAWAGUCHI Y, Shimada Y, Murakami K, Omori T, et al
    Prognostic impact of artificial intelligence-based volumetric quantification of the solid part of the tumor in clinical stage 0-I adenocarcinoma.
    Lung Cancer. 2022;170:85-90.
    PubMed     Abstract available

  63. HUSSAIN S, Klugarova J, Klugar M
    Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
    Lung Cancer. 2022;170:11-19.
    PubMed     Abstract available

    July 2022
  64. WANG X, Cai JS, Yang F
    Investigation of the non-small cell lung cancer patients with uncertain resection: A population-based study.
    Lung Cancer. 2022;171:47-55.
    PubMed     Abstract available

  65. MINEGISHI Y, Akagami T, Arai M, Saito R, et al
    Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
    Lung Cancer. 2022;172:1-8.
    PubMed     Abstract available

  66. SOLBERG S, Nilssen Y, Terje Brustugun O, Magnus Haram P, et al
    Concordance between clinical and pathology TNM-staging in lung cancer.
    Lung Cancer. 2022;171:65-69.
    PubMed     Abstract available

  67. ROBBINS HA, Zahed H, Lebrett MB, Balata H, et al
    Explaining differences in the frequency of lung cancer detection between the National Lung Screening Trial and community-based screening in Manchester, UK.
    Lung Cancer. 2022;171:61-64.
    PubMed     Abstract available

  68. VAN VEELEN A, Gulikers J, Hendriks LEL, Dursun S, et al
    Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.
    Lung Cancer. 2022;171:97-102.
    PubMed     Abstract available

  69. LIU C, Liu C, Liao J, Yin JC, et al
    Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
    Lung Cancer. 2022;171:18-25.
    PubMed     Abstract available

  70. LINDQVIST J, Jekunen A, Sihvo E, Johansson M, et al
    Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients.
    Lung Cancer. 2022;171:9-17.
    PubMed     Abstract available

  71. WOLL P, Gaunt P, Danson S, Steele N, et al
    Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.
    Lung Cancer. 2022;171:26-33.
    PubMed     Abstract available

  72. ADLER S, Yip R, Chan H, Cai Q, et al
    Comparison of lung cancer aggressiveness in patients who never smoked compared to those who smoked.
    Lung Cancer. 2022;171:90-96.
    PubMed     Abstract available

  73. SUGIMOTO T, Fujimoto D, Sato Y, Tamiya M, et al
    Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis.
    Lung Cancer. 2022;171:3-8.
    PubMed     Abstract available

  74. ARIFIN AJ, Palma DA
    The changing landscape of pneumonitis in non-small cell lung cancer.
    Lung Cancer. 2022;171:1-2.

  75. TAKADA K, Takamori S
    Comments on "Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis".
    Lung Cancer. 2022 Jul 5. pii: S0169-5002(22)00541.

  76. FROST N, Roeper J, Velthaus JL, Raspe M, et al
    Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
    Lung Cancer. 2022;170:165-175.
    PubMed     Abstract available

  77. LUIGI BANNA G, Addeo A, Zygoura P, Tsourti Z, et al
    A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Lung Cancer. 2022;169:77-83.
    PubMed     Abstract available

  78. STOGBAUER F, Lautizi M, Kriegsmann M, Winter H, et al
    Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung - Determination and validation of optimal prognostic cut-offs.
    Lung Cancer. 2022;169:1-12.
    PubMed     Abstract available

    June 2022
  79. WO Y, Li H, Zhang Y, Peng Y, et al
    The impact of station 4L lymph node dissection on short-term and long-term outcomes in non-small cell lung cancer.
    Lung Cancer. 2022;170:141-147.
    PubMed     Abstract available

  80. JIA X, Chu X, Jiang L, Li Y, et al
    Erratum to "Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram" [Lung Cancer 170 (2022) 74-84].
    Lung Cancer. 2022 Jun 29. pii: S0169-5002(22)00537.

  81. WEVER BMM, Bach S, Tibbesma M, Ter Braak TJ, et al
    Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: A feasibility study.
    Lung Cancer. 2022;170:156-164.
    PubMed     Abstract available

  82. CORDEIRO DE LIMA VC, Corassa M, Saldanha E, Freitas H, et al
    STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Lung Cancer. 2022;170:114-121.
    PubMed     Abstract available

  83. GORING S, Varol N, Waser N, Popoff E, et al
    Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
    Lung Cancer. 2022;170:122-132.
    PubMed     Abstract available

  84. GAO RW, Day CN, Yu NY, Bush A, et al
    Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.
    Lung Cancer. 2022;170:58-64.
    PubMed     Abstract available

  85. KUANG Y, Pierce CM, Chang HC, Sosinsky AZ, et al
    Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis.
    Lung Cancer. 2022 Jun 11. pii: S0169-5002(22)00469.
    PubMed     Abstract available

  86. MCKEON TP, Anil Vachani, Penning TM, Hwang WT, et al
    Air pollution and lung cancer survival in Pennsylvania.
    Lung Cancer. 2022;170:65-73.
    PubMed     Abstract available

  87. JIA X, Chu X, Jiang L, Li Y, et al
    Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram.
    Lung Cancer. 2022;170:74-84.
    PubMed     Abstract available

  88. TAKAMOCHI K, Hara K, Hayashi T, Kohsaka S, et al
    Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Lung Cancer. 2022;168:50-58.
    PubMed     Abstract available

  89. SWAMI N, Chen TY, Dee EC, Gomez SL, et al
    Adjust, don't avoid: The need for risk-based CT screening in nonsmoking populations.
    Lung Cancer. 2022;168:36-37.

  90. FANG W, Xu N, Shen Y, Gu Z, et al
    Management of incidentally detected small anterior mediastinal nodules: Which way to go?
    Lung Cancer. 2022;168:30-35.
    PubMed     Abstract available

  91. JEON YJ, Lee J, Shin S, Cho JH, et al
    Prognostic impact of micropapillary and solid histological subtype on patients undergoing curative resection for stage I lung adenocarcinoma according to the extent of pulmonary resection and lymph node assessment.
    Lung Cancer. 2022;168:21-29.
    PubMed     Abstract available

  92. JAIRAM V, Soulos PR, Gross CP, Yu JB, et al
    A reply to "Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC".
    Lung Cancer. 2022;168:84-85.

  93. LI R, Suo R, Zhang J
    Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC.
    Lung Cancer. 2022;168:83.

    May 2022
  94. SLEBE M, Pouw JEE, Hashemi SMS, Menke-van der Houven van Oordt CW, et al
    Current state and upcoming opportunities for immunoPET biomarkers in lung cancer.
    Lung Cancer. 2022;169:84-93.
    PubMed     Abstract available

  95. CUPPENS K, Baas P, Geerdens E, Cruys B, et al
    HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Lung Cancer. 2022;170:1-10.
    PubMed     Abstract available

  96. SIGEL K, Yin Kong C, Leiter A, Kale M, et al
    Assessment of treatment strategies for stage I non-small cell lung cancer in patients with comorbidities.
    Lung Cancer. 2022;170:34-40.
    PubMed     Abstract available

  97. KIM BR, Sohn JY, Jang EJ, Jo J, et al
    Hospital case-volume and mortality after lung cancer surgery: A population-based retrospective cohort study.
    Lung Cancer. 2022;169:61-66.
    PubMed     Abstract available

  98. RIUDAVETS M, Cascetta P, Planchard D
    Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
    Lung Cancer. 2022;169:102-114.
    PubMed     Abstract available

  99. DONKER HC, Schuuring E, Heitzer E, Groen HJM, et al
    Decoding circulating tumor DNA to identify durable benefit from immunotherapy in lung cancer.
    Lung Cancer. 2022;170:52-57.
    PubMed     Abstract available

  100. SOO RA, Huat Tan E, Hayashi H, Seto T, et al
    Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Lung Cancer. 2022;169:67-76.
    PubMed     Abstract available

  101. JOHNSON M, Garassino MC, Mok T, Mitsudomi T, et al
    Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
    Lung Cancer. 2022;170:41-51.
    PubMed     Abstract available

  102. KOLLER M, Musoro JZ, Tomaszewski K, Coens C, et al
    Corrigendum to "Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials" [Lung Cancer 167C (2022) 65-72].
    Lung Cancer. 2022 May 20. pii: S0169-5002(22)00436.

  103. PILOTTO S, Avancini A, Menis J, Sperduti I, et al
    Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey.
    Lung Cancer. 2022;169:94-101.
    PubMed     Abstract available

  104. MOGENET A, Barlesi F, Besse B, Michiels S, et al
    Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome.
    Lung Cancer. 2022;169:31-39.
    PubMed     Abstract available

  105. LANG C, Egger F, Alireza Hoda M, Saeed Querner A, et al
    Lymphocyte-to-monocyte ratio is an independent prognostic factor in surgically treated small cell lung cancer: An international multicenter analysis.
    Lung Cancer. 2022;169:40-46.
    PubMed     Abstract available

  106. CHU X, Xu Y, Li Y, Zhou Y, et al
    Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naive non-small cell lung cancer: An under-recognized phenomenon.
    Lung Cancer. 2022;169:22-30.
    PubMed     Abstract available

  107. WILLIAMS RM, Kareff SA, Sackstein P, Roy T, et al
    Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
    Lung Cancer. 2022;169:55-60.
    PubMed     Abstract available

  108. NGO PJ, Wade S, Vaneckova P, Behar Harpaz S, et al
    Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening.
    Lung Cancer. 2022;169:47-54.
    PubMed     Abstract available

  109. GROVER H, King W, Bhattarai N, Moloney E, et al
    Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
    Lung Cancer. 2022;170:20-33.
    PubMed     Abstract available

  110. VELUT Y, Decroix E, Blons H, Alifano M, et al
    SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
    Lung Cancer. 2022;169:13-21.
    PubMed     Abstract available

  111. RYAN DJ, Toomey S, Smyth R, Madden SF, et al
    Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel.
    Lung Cancer. 2022;168:67-73.
    PubMed     Abstract available

  112. LIU X, Li X, Zhang C, Jin J, et al
    EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
    Lung Cancer. 2022;167:78-86.
    PubMed     Abstract available

  113. MEDERER T, Elsner F, Robold T, Grosser C, et al
    EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients.
    Lung Cancer. 2022;167:73-77.
    PubMed     Abstract available

  114. YOSHIDA C, Kadota K, Yamada K, Fujimoto S, et al
    Tumor-associated CD163(+) macrophage as a predictor of tumor spread through air spaces and with CD25(+) lymphocyte as a prognostic factor in resected stage I lung adenocarcinoma.
    Lung Cancer. 2022;167:34-40.
    PubMed     Abstract available

  115. LI W, Ye L, Huang Y, Zhou F, et al
    Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
    Lung Cancer. 2022;167:25-33.
    PubMed     Abstract available

  116. CAMERON JK, Aitken J, Reid A, Mengersen K, et al
    Geographic distribution of malignant mesothelioma incidence and survival in Australia.
    Lung Cancer. 2022;167:17-24.
    PubMed     Abstract available

  117. SCHERPEREEL A, Antonia S, Bautista Y, Grossi F, et al
    First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Lung Cancer. 2022;167:8-16.
    PubMed     Abstract available

  118. GARCIA BNC, van Kempen LC, Kuijpers CCHJ, Schuuring E, et al
    Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
    Lung Cancer. 2022;167:1-7.
    PubMed     Abstract available

  119. MC LEER A, Foll M, Brevet M, Antoine M, et al
    Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
    Lung Cancer. 2022;167:98-106.
    PubMed     Abstract available

    April 2022
  120. TUFMAN A, Redmond K, Giannopoulou A, Gonzalez-McQuire S, et al
    Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey.
    Lung Cancer. 2022;168:59-66.
    PubMed     Abstract available

  121. DICKSON JL, Bhamani A, Quaife SL, Horst C, et al
    The reporting of pulmonary nodule results by letter in a lung cancer screening setting.
    Lung Cancer. 2022;168:46-49.
    PubMed     Abstract available

  122. SCHEFFLER M, Wiesweg M, Michels S, Nogova L, et al
    Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
    Lung Cancer. 2022;168:10-20.
    PubMed     Abstract available

  123. HAYASHI H, Yonesaka K, Nakamura A, Fujimoto D, et al
    Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
    Lung Cancer. 2022;168:38-45.
    PubMed     Abstract available

  124. ZHOU Y, Song L, Xu Q, Zeng L, et al
    Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
    Lung Cancer. 2022;167:58-64.
    PubMed     Abstract available

  125. LEBRETT MB, Crosbie EJ, Yorke J, Hewitt K, et al
    Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme.
    Lung Cancer. 2022;168:1-9.
    PubMed     Abstract available

  126. TORASAWA M, Yoshida T, Yagishita S, Shimoda Y, et al
    Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.
    Lung Cancer. 2022;167:49-57.
    PubMed     Abstract available

  127. STEEGHS EMP, Groen HJM, Schuuring E, Aarts MJ, et al
    Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
    Lung Cancer. 2022;167:87-97.
    PubMed     Abstract available

  128. FOURNEL L, Charrier T, Huriet M, Iaffaldano A, et al
    Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients.
    Lung Cancer. 2022;166:221-227.
    PubMed     Abstract available

  129. LI H, Sun Z, Li Y, Qi Q, et al
    Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions.
    Lung Cancer. 2022;166:178-188.
    PubMed     Abstract available

  130. ARCANGELI S, Ramella S
    Postoperative radiotherapy (PORT) in NSCLC: The end of a love? It is never too good to trust what appears.
    Lung Cancer. 2022;166:250-251.

  131. LI Y, Shi X, Mao B, Wang L, et al
    The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8(+) T cell infiltration in Chinese lung large cell neuroendocrine carcinoma.
    Lung Cancer. 2022;166:161-169.
    PubMed     Abstract available

  132. FENG XL, Wang SZ, Chen HH, Huang YX, et al
    Optimizing the radiomics-machine-learning model based on non-contrast enhanced CT for the simplified risk categorization of thymic epithelial tumors: A large cohort retrospective study.
    Lung Cancer. 2022;166:150-160.
    PubMed     Abstract available

  133. SKRIBEK M, Bozoky B, Tsakonas G
    Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report.
    Lung Cancer. 2022;166:132-134.
    PubMed     Abstract available

  134. SLIMANO F, Le Bozec A, Cransac A, Foucher P, et al
    Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.
    Lung Cancer. 2022;166:114-121.
    PubMed     Abstract available

  135. LEVY B, Barlesi F, Paz-Ares L, Bennouna J, et al
    Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).
    Lung Cancer. 2022;166:107-113.
    PubMed     Abstract available

  136. LIN L, Pan H, Li X, Zhao C, et al
    A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2022;166:98-106.
    PubMed     Abstract available

  137. COPIA SPERANDIO R, Luiza Teixeira Tostes F, Vidal Campregher P, Ribeiro Paes V, et al
    EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
    Lung Cancer. 2022;166:94-97.
    PubMed     Abstract available

  138. NAIDOO J, Vansteenkiste JF, Faivre-Finn C, Ozguroglu M, et al
    Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
    Lung Cancer. 2022;166:84-93.
    PubMed     Abstract available

  139. JOUBERT V, Chalabreysse L, Gamondes D, Tronc F, et al
    Clinical practices for non-neoplastic thymic lesions: Results from a multidisciplinary cohort.
    Lung Cancer. 2022;166:76-83.
    PubMed     Abstract available

  140. VOLTERRANI L, Guerrini S, Zanfrini E, Grassi A, et al
    "HRCT predictors of GGO surgical resection: Histopathological and molecular correlation in the era of lung sparing surgery".
    Lung Cancer. 2022;166:70-75.
    PubMed     Abstract available

  141. VELEZ MA, Tsai HHC, Shackelford DB, Garon EB, et al
    What is the current role of immunotherapy in EGFR mutant advanced NSCLC?
    Lung Cancer. 2022;166:253-254.

  142. BAUML JM, Li BT, Velcheti V, Govindan R, et al
    Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
    Lung Cancer. 2022;166:270-278.
    PubMed     Abstract available

  143. TAN C, Mandell JD, Dasari K, Cannataro VL, et al
    Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors-on average-to exhibit a lower mutation burden.
    Lung Cancer. 2022;166:265-269.

    March 2022
  144. KOLLER M, Musoro JZ, Tomaszewski K, Coens C, et al
    Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.
    Lung Cancer. 2022;167:65-72.
    PubMed     Abstract available

  145. TAN F, Bi N, Zhang H, Li R, et al
    External validation of the eighth edition of the TNM classification for lung cancer in small cell lung cancer.
    Lung Cancer. 2022;170:98-104.
    PubMed     Abstract available

  146. VAN DER WEIJST L, Aguado-Barrera ME, Azria D, Berkovic P, et al
    Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).
    Lung Cancer. 2022;166:228-241.
    PubMed     Abstract available

  147. ROBERT NJ, Espirito JL, Chen L, Nwokeji E, et al
    Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network biomarker testing in metastatic NSCLC with first-line therapy.
    Lung Cancer. 2022;166:197-204.
    PubMed     Abstract available

  148. ZHU YJ, Chang XS, Zhou R, Chen YD, et al
    Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.
    Lung Cancer. 2022;166:189-196.
    PubMed     Abstract available

  149. MCLEAN AEB, Kao SC, Barnes DJ, Wong KKH, et al
    Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132].
    Lung Cancer. 2022 Mar 9. pii: S0169-5002(22)00367.

  150. JUAREZ-GARCIA A, Sharma R, Hunger M, Kayaniyil S, et al
    Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
    Lung Cancer. 2022;166:205-220.
    PubMed     Abstract available

  151. MINCHOM A, Viteri S, Bazhenova L, Gadgeel SM, et al
    Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Lung Cancer. 2022;168:74-82.
    PubMed     Abstract available

  152. BUTTER R, Hondelink LM, van Elswijk L, Blaauwgeers JLG, et al
    The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.
    Lung Cancer. 2022;166:143-149.
    PubMed     Abstract available

  153. EDELMAN MJ, Dvorkin M, Laktionov K, Navarro A, et al
    Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
    Lung Cancer. 2022;166:135-142.
    PubMed     Abstract available

  154. SANTORO A, Su WC, Navarro A, Simonelli M, et al
    Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2022;166:170-177.
    PubMed     Abstract available

  155. CLAERHOUT S, Lehnert S, Vander Borght S, Spans L, et al
    Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
    Lung Cancer. 2022;166:242-249.
    PubMed     Abstract available

    February 2022
  156. NGO PJ, Cressman S, Behar-Harpaz S, Karikios DJ, et al
    Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods.
    Lung Cancer. 2022;166:122-131.
    PubMed     Abstract available

  157. SUN K, Li M, Shang M, Su X, et al
    Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance.
    Lung Cancer. 2022;166:63-69.
    PubMed     Abstract available

  158. KILLINGBERG KT, Halvorsen TO, Flotten O, Brustugun OT, et al
    Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
    Lung Cancer. 2022;166:49-57.
    PubMed     Abstract available

  159. ILIE M, Beaulande M, Long-Mira E, Bontoux C, et al
    Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer.
    Lung Cancer. 2022;166:1-8.
    PubMed     Abstract available

  160. TANG M, Lee CK, Lewis CR, Boyer M, et al
    Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.
    Lung Cancer. 2022;166:40-48.
    PubMed     Abstract available

  161. SCHMID S, Garcia M, Cheng S, Zhan L, et al
    Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2022;166:58-62.
    PubMed     Abstract available

  162. PAZ-ARES L, Gondos A, Saldana D, Thomas M, et al
    Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
    Lung Cancer. 2022;167:41-48.
    PubMed     Abstract available

  163. SOUQUET PJ, Audigier-Valette C, Molinier O, Cortot A, et al
    Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.
    Lung Cancer. 2022;164:84-90.
    PubMed     Abstract available

  164. ARMATO SG, Nowak AK, Francis RJ, Katz SI, et al
    Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group.
    Lung Cancer. 2022;164:76-83.
    PubMed     Abstract available

  165. NAGASAKA M, Balmanoukian AS, Madison R, Zhang SS, et al
    Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis.
    Lung Cancer. 2022;164:52-55.
    PubMed     Abstract available

  166. BOCH T, Frost N, Sommer L, Overbeck TR, et al
    Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
    Lung Cancer. 2022;164:46-51.
    PubMed     Abstract available

  167. CHEN S, Ye T, Yang S, Zhao Y, et al
    Prognostic implication of tumor spread through air spaces in patients with pathologic N0 lung adenocarcinoma.
    Lung Cancer. 2022;164:33-38.
    PubMed     Abstract available

  168. JAKOBSEN AK, Yuusufi S, Madsen LB, Meldgaard P, et al
    TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data.
    Lung Cancer. 2022;164:23-32.
    PubMed     Abstract available

  169. ZHANG S, Lin D, Yu Y, Cao Q, et al
    Which will carry more weight when CTR > 0.5, solid component size, CTR, tumor size or SUVmax?
    Lung Cancer. 2022;164:14-22.
    PubMed     Abstract available

  170. RODRIGUEZ-ABREU D, Cobo M, Garcia-Roman S, Viteri-Ramirez S, et al
    The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
    Lung Cancer. 2022;164:8-13.
    PubMed     Abstract available

  171. DEBIEUVRE D, Dayen C, Dixmier A, Pau D, et al
    FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
    Lung Cancer. 2022;164:1-7.
    PubMed     Abstract available

    January 2022
  172. WU J, Hou L, E H, Zhao Y, et al
    Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.
    Lung Cancer. 2022;165:115-123.
    PubMed     Abstract available

  173. ZHANG J, IJzerman MJ, Oberoi J, Karnchanachari N, et al
    Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes.
    Lung Cancer. 2022;166:27-39.
    PubMed     Abstract available

  174. HUANG LT, Zhang SL, Han CB, Ma JT, et al
    Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Lung Cancer. 2022;166:9-16.
    PubMed     Abstract available

  175. ZHAO JJ, Chan HP, Soon YY, Huang Y, et al
    A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer.
    Lung Cancer. 2022;166:17-26.
    PubMed     Abstract available

  176. CUI W, Milner-Watts C, McVeigh TP, Minchom A, et al
    A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.
    Lung Cancer. 2022;165:34-42.
    PubMed     Abstract available

  177. MCLEAN AEB, Kao SC, Barnes DJ, Wong KKH, et al
    The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment.
    Lung Cancer. 2022;165:124-132.
    PubMed     Abstract available

  178. LI M, Hou X, Chen J, Zhang B, et al
    ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061).
    Lung Cancer. 2022;165:54-62.
    PubMed     Abstract available

  179. CHEN Y, Yang H, Cheng Z, Chen L, et al
    A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer.
    Lung Cancer. 2022;165:18-27.
    PubMed     Abstract available

  180. DEBOEVER N, McGrail DJ, Lee Y, Tran HT, et al
    Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.
    Lung Cancer. 2022;164:69-75.
    PubMed     Abstract available

  181. OBIOLS C, Call S, Rami-Porta R, Jaen A, et al
    Radicality of lymphadenectomy in lung cancer resections by thoracotomy and video-assisted thoracoscopic approach: A prospective, multicentre and propensity-score adjusted study.
    Lung Cancer. 2022;165:63-70.
    PubMed     Abstract available

  182. LANCASTER HL, Zheng S, Aleshina OO, Yu D, et al
    Outstanding negative prediction performance of solid pulmonary nodule volume AI for ultra-LDCT baseline lung cancer screening risk stratification.
    Lung Cancer. 2022;165:133-140.
    PubMed     Abstract available

  183. FUKUI M, Suzuki K, Ando K, Matsunaga T, et al
    Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia.
    Lung Cancer. 2022;165:108-114.
    PubMed     Abstract available

  184. YANG S, Shih YT, Huo J, Mehta HJ, et al
    Procedural complications associated with invasive diagnostic procedures after lung cancer screening with low-dose computed tomography.
    Lung Cancer. 2022;165:141-144.
    PubMed     Abstract available

  185. LIAO G, Huang L, Wu S, Zhang P, et al
    Preoperative CT-based peritumoral and tumoral radiomic features prediction for tumor spread through air spaces in clinical stage I lung adenocarcinoma.
    Lung Cancer. 2022;163:87-95.
    PubMed     Abstract available

  186. KLEBE S, Galateau Salle F, Bruno R, Brcic L, et al
    The highlights of the 15th international conference of the international mesothelioma interest group - Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?
    Lung Cancer. 2022;163:1-6.
    PubMed     Abstract available

    December 2021
  187. HE LN, Chen T, Fu S, Chen C, et al
    Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
    Lung Cancer. 2021;165:10-17.
    PubMed     Abstract available

  188. EVERS J, Hendriks LEL, De Jaeger K, Wijsman R, et al
    Corrigendum to "Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands" [Lung Cancer 162C (2021) 61-70].
    Lung Cancer. 2021 Dec 29. pii: S0169-5002(21)00640.

  189. COLEMAN N, Harbery A, Heuss S, Vivanco I, et al
    Targeting un-MET needs in advanced non-small cell lung cancer.
    Lung Cancer. 2021;164:56-68.
    PubMed     Abstract available

  190. CHANG J, Wu YL, Lu S, Wang J, et al
    Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
    Lung Cancer. 2021;165:71-81.
    PubMed     Abstract available

  191. KENMOTSU H, Mori K, Mizuno R, Mamesaya N, et al
    Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naive patients with extensive-stage small-cell lung cancer.
    Lung Cancer. 2021;164:39-45.
    PubMed     Abstract available

  192. DESAI A, Abdayem P, Adjei AA, Planchard D, et al
    Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Lung Cancer. 2021;163:96-106.
    PubMed     Abstract available

  193. MURAKAMI H, Horinouchi H, Harada H, Sobue T, et al
    Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study.
    Lung Cancer. 2021;165:152-163.
    PubMed     Abstract available

  194. FRIESE-HAMIM M, Clark A, Perrin D, Crowley L, et al
    Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
    Lung Cancer. 2021;163:77-86.
    PubMed     Abstract available

  195. LIN T, Pham J, Paul E, Conron M, et al
    Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study.
    Lung Cancer. 2021;163:69-76.
    PubMed     Abstract available

  196. MAINGUENE J, Basse C, Girard P, Beaucaire-Danel S, et al
    Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.
    Lung Cancer. 2021;163:51-58.
    PubMed     Abstract available

  197. RIUDAVETS M, Naigeon M, Texier M, Dorta M, et al
    Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
    Lung Cancer. 2021 Dec 3. pii: S0169-5002(21)00624.
    PubMed     Abstract available

  198. MARKS S, Naidoo J
    Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
    Lung Cancer. 2021;163:59-68.
    PubMed     Abstract available

  199. HA DM, Prochazka AV, Bekelman DB, Stevens-Lapsley JE, et al
    Modifiable factors associated with health-related quality of life among lung cancer survivors following curative intent therapy.
    Lung Cancer. 2021;163:42-50.
    PubMed     Abstract available

  200. BRYANT AK, Sankar K, Strohbehn GW, Zhao L, et al
    Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2021;163:35-41.
    PubMed     Abstract available

  201. GUO LW, Lyu ZY, Meng QC, Zheng LY, et al
    A risk prediction model for selecting high-risk population for computed tomography lung cancer screening in China.
    Lung Cancer. 2021;163:27-34.
    PubMed     Abstract available

  202. PLUMMER R, Dean E, Arkenau HT, Redfern C, et al
    A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2021;163:19-26.
    PubMed     Abstract available

  203. BAAS P, Daumont MJ, Lacoin L, Penrod JR, et al
    Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
    Lung Cancer. 2021;162:185-193.
    PubMed     Abstract available

  204. KWOK WC, Chiang KY, Ho JCM, Lam DCL, et al
    Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung.
    Lung Cancer. 2021;162:169-174.
    PubMed     Abstract available

  205. NOWAK AK, Chin WL, Keam S, Cook A, et al
    Immune checkpoint inhibitor therapy for malignant pleural mesothelioma.
    Lung Cancer. 2021;162:162-168.
    PubMed     Abstract available

  206. BAZHENOVA L, Minchom A, Viteri S, Bauml JM, et al
    Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.
    Lung Cancer. 2021;162:154-161.
    PubMed     Abstract available

  207. SUZUKI M, Matsumoto Y, Imabayashi T, Teishikata T, et al
    Cryobiopsy as a reliable technique for the preoperative identification of micropapillary/solid components in early-stage lung adenocarcinoma.
    Lung Cancer. 2021;162:147-153.
    PubMed     Abstract available

  208. SAITO T, Ono R, Tanaka Y, Tatebayashi D, et al
    The effect of home-based preoperative pulmonary rehabilitation before lung resection: A retrospective cohort study.
    Lung Cancer. 2021;162:135-139.
    PubMed     Abstract available

  209. FJAELLEGAARD K, Koefod Petersen J, Reuter S, Malene Fischer B, et al
    Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis.
    Lung Cancer. 2021;162:106-118.
    PubMed     Abstract available

  210. WU Y, Yang M, Chen R, Ou SI, et al
    Diverse responses to EGFR-TKIs in patients with concurrent germline and somatic EGFR mutations.
    Lung Cancer. 2021;162:207-209.

  211. LIANG Q, Xu H, Liu Y, Zhang W, et al
    Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Lung Cancer. 2021;162:86-89.
    PubMed     Abstract available

  212. FILIPPI AR, Garassino M, Shirvani SM, Feldman J, et al
    Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy - A path forward?
    Lung Cancer. 2021;162:203-206.

  213. HAMADA A, Suda K, Koga T, Fujino T, et al
    In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
    Lung Cancer. 2021;162:79-85.
    PubMed     Abstract available

  214. SCHAKENRAAD A, Hashemi S, Twisk J, Houda I, et al
    The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors.
    Lung Cancer. 2021;162:36-41.
    PubMed     Abstract available

  215. CHIEN YN, Lin YC, Chang CL, Lin WC, et al
    Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinoma who received and responded to tyrosine kinase inhibitor treatment.
    Lung Cancer. 2021;162:29-35.
    PubMed     Abstract available

  216. GUTIERREZ M, Guo R, Giaccone G, Liu SV, et al
    Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers.
    Lung Cancer. 2021;162:23-28.
    PubMed     Abstract available

  217. POPAT S, Jung HA, Lee SY, Hochmair MJ, et al
    Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Lung Cancer. 2021;162:9-15.
    PubMed     Abstract available

    November 2021
  218. KOK PS, Lee K, Lord S, John T, et al
    Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer.
    Lung Cancer. 2021;163:14-18.
    PubMed     Abstract available

  219. TAN DS, Thomas M, Kim DW, Szpakowski S, et al
    Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Lung Cancer. 2021;163:7-13.
    PubMed     Abstract available

  220. MATSUMOTO K, Shiroyama T, Kuge T, Miyake K, et al
    Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021;162:175-184.
    PubMed     Abstract available

  221. LIU Q, Qiao M, Lohinai Z, Mao S, et al
    CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer.
    Lung Cancer. 2021 Nov 11. pii: S0169-5002(21)00596.
    PubMed     Abstract available

  222. ISAKA T, Ito H, Nakayama H, Yokose T, et al
    Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
    Lung Cancer. 2021;162:128-134.
    PubMed     Abstract available

  223. GIRARD N, Perol M, Simon G, Audigier Valette C, et al
    Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.
    Lung Cancer. 2021;162:119-127.
    PubMed     Abstract available

  224. CROCKETT C, Belderbos J, Levy A, McDonald F, et al
    Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?
    Lung Cancer. 2021;162:96-105.
    PubMed     Abstract available

  225. ZHU Y, Cai Q, Wang Y, You N, et al
    Pre-surgical assessment of mediastinal lymph node metastases in patients having >/= 30 mm non-small-cell lung cancers.
    Lung Cancer. 2021;161:189-196.
    PubMed     Abstract available

  226. TAKAMOCHI K, Hara K, Hayashi T, Kohsaka S, et al
    Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Lung Cancer. 2021;161:163-170.
    PubMed     Abstract available

  227. CIRNE F, Zhou S, Kappel C, El-Kadi A, et al
    ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.
    Lung Cancer. 2021;161:9-17.
    PubMed     Abstract available

  228. ZHOU N, Velez MA, Bachrach B, Gukasyan J, et al
    Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
    Lung Cancer. 2021;161:34-41.
    PubMed     Abstract available

    October 2021
  229. EVERS J, Hendriks LEL, De Jaeger K, Wijsman R, et al
    Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;162:61-70.
    PubMed     Abstract available

  230. GAO L, Shen L, Wang K, Lu S, et al
    Propensity score matched analysis for the role of surgery in stage small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital.
    Lung Cancer. 2021;162:54-60.
    PubMed     Abstract available

  231. DEMEDTS I, Himpe U, Bossuyt J, Anthoons G, et al
    Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients.
    Lung Cancer. 2021;162:90-95.
    PubMed     Abstract available

  232. POMPILI C, Rogers Z, Absolom K, Holch P, et al
    Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study.
    Lung Cancer. 2021;162:71-78.
    PubMed     Abstract available

  233. BUMA AIG, Muller M, de Vries R, Sterk PJ, et al
    Corrigendum to "eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer" [Lung Cancer 160 (2021) 36-43].
    Lung Cancer. 2021 Oct 22. pii: S0169-5002(21)00576.

  234. YASUDA H, Ichihara E, Sakakibara-Konishi J, Zenke Y, et al
    A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
    Lung Cancer. 2021;162:140-146.
    PubMed     Abstract available

  235. MONDACA S, Lebow ES, Namakydoust A, Razavi P, et al
    Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73].
    Lung Cancer. 2021 Oct 5. pii: S0169-5002(21)00552.

  236. ZHOU N, Jiang M, Li T, Zhu J, et al
    Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.
    Lung Cancer. 2021;160:111-117.
    PubMed     Abstract available

  237. TOTA V, Dagonnier M, Wery D, Binet L, et al
    Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review.
    Lung Cancer. 2021;160:59-65.
    PubMed     Abstract available

  238. SHAH P, Sands J, Normanno N
    The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.
    Lung Cancer. 2021;160:118-126.
    PubMed     Abstract available

  239. LIU D, Xu X, Wen J, Zhang C, et al
    Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
    Lung Cancer. 2021;160:32-35.
    PubMed     Abstract available

  240. AOKAGE K, Miyoshi T, Wakabayashi M, Ikeno T, et al
    Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
    Lung Cancer. 2021;160:8-16.
    PubMed     Abstract available

    September 2021
  241. MODY GN, Stover AM, Wang M, King-Kallimanis BL, et al
    Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).
    Lung Cancer. 2021;162:1-8.
    PubMed     Abstract available

  242. LI M, Zhang C, Deng S, Li L, et al
    Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer.
    Lung Cancer. 2021;162:16-22.
    PubMed     Abstract available

  243. JOOSTEN PJM, de Langen AJ, van der Noort V, Monkhorst K, et al
    The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
    Lung Cancer. 2021;161:141-151.
    PubMed     Abstract available

  244. TU Z, Li C, Tian T, Chen Q, et al
    A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion.
    Lung Cancer. 2021;161:114-121.
    PubMed     Abstract available

  245. KRAMER T, Annema JT
    Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer.
    Lung Cancer. 2021;161:152-162.
    PubMed     Abstract available

  246. MAAT APWM, Cornelissen R, Bogers AJJC, Mahtab EAF, et al
    Erratum to "Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions''' [Lung Cancer 159 (2021) 127].
    Lung Cancer. 2021 Sep 20. pii: S0169-5002(21)00539.

  247. BALATA H, Ruparel M, O'Dowd E, Ledson M, et al
    Analysis of the baseline performance of five UK lung cancer screening programmes.
    Lung Cancer. 2021;161:136-140.
    PubMed     Abstract available

  248. BARANY N, Rozsas A, Megyesfalvi Z, Grusch M, et al
    Clinical relevance of circulating activin A and follistatin in small cell lung cancer.
    Lung Cancer. 2021;161:128-135.
    PubMed     Abstract available

  249. AULIAC JB, Monnet I, Bizieux A, Greillier L, et al
    Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
    Lung Cancer. 2021;161:122-127.
    PubMed     Abstract available

  250. JAIRAM V, Pasha S, Soulos PR, Gross CP, et al
    Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques.
    Lung Cancer. 2021;161:171-179.
    PubMed     Abstract available

  251. CLARKE JM, Patel JD, Robert F, Kio EA, et al
    Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
    Lung Cancer. 2021;161:180-188.
    PubMed     Abstract available

  252. HARADA G, Santini FC, Wilhelm C, Drilon A, et al
    NTRK fusions in lung cancer: From biology to therapy.
    Lung Cancer. 2021;161:108-113.
    PubMed     Abstract available

  253. AGGARWAL C, Bubendorf L, Cooper WA, Illei P, et al
    Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
    Lung Cancer. 2021;162:42-53.
    PubMed     Abstract available

  254. BOUDY AS, Grausz N, Selleret L, Gligorov J, et al
    Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma.
    Lung Cancer. 2021;161:68-75.
    PubMed     Abstract available

  255. WINKELMAN JA, van der Woude L, Heineman DJ, Bahce I, et al
    A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S).
    Lung Cancer. 2021;161:42-48.
    PubMed     Abstract available

  256. SAITO G, Oya Y, Taniguchi Y, Kawachi H, et al
    Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Lung Cancer. 2021;161:86-93.
    PubMed     Abstract available

  257. CASTELLANOS SH, Pagano A, Plodkowski AJ, Girshman J, et al
    Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
    Lung Cancer. 2021;161:60-67.
    PubMed     Abstract available

  258. ANDREANO A, Bergamaschi W, Russo AG
    Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort.
    Lung Cancer. 2021;159:145-152.
    PubMed     Abstract available

  259. GAO J, Zhang L, Li Z, Wang F, et al
    UniPortal thoracoscopic pneumonectomy does not compromise perioperative and long-term survival in patients with NSCLC: A retrospective, multicenter, and propensity score matching study.
    Lung Cancer. 2021;159:135-144.
    PubMed     Abstract available

  260. Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions'.
    Lung Cancer. 2021;159:127.

  261. BITTONI M, Yang JC, Shih JY, Peled N, et al
    Real-world insights into patients with advanced NSCLC and MET alterations.
    Lung Cancer. 2021;159:96-106.
    PubMed     Abstract available

  262. KIM RY, Li Y, Marmarelis ME, Vachani A, et al
    Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Lung Cancer. 2021;159:107-110.
    PubMed     Abstract available

  263. OIWA H, Aokage K, Suzuki A, Sato K, et al
    Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis.
    Lung Cancer. 2021;159:74-83.
    PubMed     Abstract available

  264. MONDACA S, Lebow ES, Namakydoust A, Razavi P, et al
    Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
    Lung Cancer. 2021;159:66-73.
    PubMed     Abstract available

  265. SEBAN RD, Assie JB, Giroux-Leprieur E, Massiani MA, et al
    Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Lung Cancer. 2021;159:45-55.
    PubMed     Abstract available

  266. MAUCLET C, Collard P, Ghaye B, Hoton D, et al
    Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF(V600) mutation as an acquired resistance mechanism.
    Lung Cancer. 2021;159:42-44.
    PubMed     Abstract available

  267. LAM TC, Tsang KC, Choi HC, Lee VH, et al
    Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
    Lung Cancer. 2021;159:18-26.
    PubMed     Abstract available

  268. DEMPKE WCM, Reck M
    KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
    Lung Cancer. 2021;159:10-17.
    PubMed     Abstract available

  269. ZHANG J, Huang J, Li Q, Lin H, et al
    DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
    Lung Cancer. 2021;159:171-174.

  270. CHANG HC, Ko PH, Chang YS, Chou PC, et al
    Acute generalized exanthematous pustulosis induced by atezolizumab in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;159:175-176.

  271. ROSSI UG, Rossi GA
    Pulmonary anatomy, pathology and treatment: What will be the artificial intelligence and deep-learning role on them?
    Lung Cancer. 2021;159:181-182.

    August 2021
  272. MORIMOTO K, Yamada T, Yokoi T, Kijima T, et al
    Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2021;161:26-33.
    PubMed     Abstract available

  273. NORO R, Igawa S, Bessho A, Hirose T, et al
    A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
    Lung Cancer. 2021;161:49-54.
    PubMed     Abstract available

  274. NAGASAKA M, Asad MFB, Al Hallak MN, Uddin MH, et al
    Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).
    Lung Cancer. 2021;160:92-98.
    PubMed     Abstract available

  275. MOORE DA, Benafif S, Poskitt B, Argue S, et al
    Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.
    Lung Cancer. 2021;161:55-59.
    PubMed     Abstract available

  276. KULASINGHE A, O'Leary C, Monkman J, Bharti V, et al
    The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2021;160:73-77.
    PubMed     Abstract available

  277. VOGGEL S, Abele M, Seitz C, Agaimy A, et al
    Primary lung carcinoma in children and adolescents - Clinical characteristics and outcome of 12 cases from the German registry for rare paediatric tumours (STEP).
    Lung Cancer. 2021;160:66-72.
    PubMed     Abstract available

  278. CHEUNG CC, Smith AC, Albadine R, Bigras G, et al
    Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
    Lung Cancer. 2021;160:127-135.
    PubMed     Abstract available

  279. VAUCHIER C, Pluvy J, Theou-Anton N, Soussi G, et al
    Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.
    Lung Cancer. 2021;160:28-31.
    PubMed     Abstract available

  280. STEENDAM CMJ, Peric R, van Walree NC, Youssef M, et al
    Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.
    Lung Cancer. 2021;160:44-49.
    PubMed     Abstract available

  281. VERMA V
    Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?
    Lung Cancer. 2021 Aug 3. pii: S0169-5002(21)00485.

  282. BUMA AIG, Muller M, de Vries R, Sterk PJ, et al
    eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.
    Lung Cancer. 2021;160:36-43.
    PubMed     Abstract available

  283. ZHANG SS, Nagasaka M, Zhu VW, Ou SI, et al
    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Lung Cancer. 2021;158:126-136.
    PubMed     Abstract available

  284. NAKASONE S, Suzuki A, Okazaki H, Onodera K, et al
    Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.
    Lung Cancer. 2021;158:115-125.
    PubMed     Abstract available

  285. TOMASIK B, Bienkowski M, Braun M, Popat S, et al
    Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score >/=2 - Systematic review and meta-analysis.
    Lung Cancer. 2021;158:97-106.
    PubMed     Abstract available

  286. YOSHIDA C, Kadota K, Ikeda T, Ibuki E, et al
    Tumor-associated macrophage infiltration is associated with a higher rate of tumor spread through air spaces in resected lung adenocarcinomas.
    Lung Cancer. 2021;158:91-96.
    PubMed     Abstract available

  287. HE Z, Zhu X, Zeng Q, Yu Z, et al
    A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;158:164-165.

  288. FEKKAR A, Emprou C, Lefebvre C, Ferretti G, et al
    Thoracic NUT carcinoma: Common pathological features despite diversity of clinical presentations.
    Lung Cancer. 2021;158:55-59.
    PubMed     Abstract available

  289. LU A, Shi Y, Liu Y, Lin J, et al
    Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma.
    Lung Cancer. 2021;158:29-39.
    PubMed     Abstract available

  290. LIU SV
    NRG1 fusions: Biology to therapy.
    Lung Cancer. 2021;158:25-28.
    PubMed     Abstract available

  291. KUIJVENHOVEN JC, Livi V, Szlubowski A, Ninaber M, et al
    Endobronchial ultrasound for T4 staging in patients with resectable NSCLC.
    Lung Cancer. 2021;158:18-24.
    PubMed     Abstract available

  292. CYTRYN S, Ferreira V, Boland P, Chachoua A, et al
    Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
    Lung Cancer. 2021;158:15-17.
    PubMed     Abstract available

  293. INGLEY KM, Hughes D, Hubank M, Lindsay D, et al
    Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
    Lung Cancer. 2021;158:151-155.
    PubMed     Abstract available

  294. CHEN X, Xu BO, Fu F, Cai K, et al
    A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK+ in NSCLC.
    Lung Cancer. 2021;158:162-163.

    July 2021
  295. YOH K, Matsumoto S, Furuya N, Nishino K, et al
    Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2021;159:128-134.
    PubMed     Abstract available

  296. KOOMEN BM, Voorham QJM, Epskamp-Kuijpers CCHJ, van Dooijeweert C, et al
    Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients.
    Lung Cancer. 2021;159:117-126.
    PubMed     Abstract available

  297. KOZONO DE, Stinchcombe TE, Salama JK, Bogart J, et al
    Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2021;159:56-65.
    PubMed     Abstract available

  298. ZHAO M, Wu J, Deng J, Wang T, et al
    Proposal for Rib invasion as an independent T descriptor for non-small cell lung cancer: A propensity-score matching analysis.
    Lung Cancer. 2021;159:27-33.
    PubMed     Abstract available

  299. DIAZ M, Garcia M, Vidal C, Santiago A, et al
    Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis.
    Lung Cancer. 2021;159:153-161.
    PubMed     Abstract available

  300. SAFAVI AH, Mak DY, Boldt RG, Chen H, et al
    Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021 Jul 21. pii: S0169-5002(21)00472.
    PubMed     Abstract available

  301. WANG X, Guo Y, Liu L, Wei J, et al
    YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes.
    Lung Cancer. 2021 Jul 21. pii: S0169-5002(21)00456.
    PubMed     Abstract available

  302. RAD HS, Rad HS, Shiravand Y, Radfar P, et al
    The Pandora's box of novel technologies that may revolutionize lung cancer.
    Lung Cancer. 2021;159:34-41.
    PubMed     Abstract available

  303. VAN BREESCHOTEN J, Ismail R, Smit H, Schuurbiers O, et al
    An invisible group of COVID-19 victims; impact on Dutch lung cancer care.
    Lung Cancer. 2021 Jul 19. pii: S0169-5002(21)00476.

  304. CHO BC, Yoh K, Perets R, Nagrial A, et al
    Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Lung Cancer. 2021;159:162-170.
    PubMed     Abstract available

  305. SHEN Y, Zhang Y, Guo Y, Li W, et al
    Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis.
    Lung Cancer. 2021;159:111-116.
    PubMed     Abstract available

  306. KOCHER F, Tymoszuk P, Amann A, Sprung S, et al
    Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.
    Lung Cancer. 2021;159:84-95.
    PubMed     Abstract available

  307. USUZAKI T, Takahashi K, Umemiya K, Ishikuro M, et al
    Augmentation method for convolutional neural network that improves prediction performance in the task of classifying primary lung cancer and lung metastasis using CT images.
    Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00468.

  308. LINDSAY CR, Garassino MC, Nadal E, Ohrling K, et al
    On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00474.
    PubMed     Abstract available

  309. BHALLA S, Bakouny Z, Schmidt AL, Labaki C, et al
    Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.
    Lung Cancer. 2021;160:78-83.
    PubMed     Abstract available

  310. FUNG AS, Graham DM, Chen EX, Stockley TL, et al
    A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
    Lung Cancer. 2021;157:21-29.
    PubMed     Abstract available

  311. POPAT S, Brustugun OT, Cadranel J, Felip E, et al
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer. 2021;157:9-16.
    PubMed     Abstract available

  312. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
    Lung Cancer. 2021;157:167.

  313. CLERMIDY H, Maury JM, Collaud S, Drevet G, et al
    Lymph Node Dissection in Thymoma: Is it worth it?
    Lung Cancer. 2021;157:156-162.
    PubMed     Abstract available

  314. XIE XJ, Liu SY, Chen JY, Zhao Y, et al
    Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
    Lung Cancer. 2021;157:30-39.
    PubMed     Abstract available

  315. TALCOTT WJ, Miccio JA, Park HS, White AA, et al
    Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
    Lung Cancer. 2021;157:17-20.
    PubMed     Abstract available

  316. ZHU VW, Zhao JJ, Gao Y, Syn NL, et al
    Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Lung Cancer. 2021;157:147-155.
    PubMed     Abstract available

  317. LESIRE B, Durieux V, Grigoriu B, Girard N, et al
    Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.
    Lung Cancer. 2021;157:131-146.
    PubMed     Abstract available

  318. SUGIMOTO A, Umemura S, Miyoshi T, Nakai T, et al
    High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Lung Cancer. 2021;157:1-8.
    PubMed     Abstract available

  319. YANG Y, Ran J, Wang Y, Zhou Z, et al
    Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases.
    Lung Cancer. 2021;157:116-123.
    PubMed     Abstract available

  320. PASSIGLIA F, Leone G, Olmetto E, Delcuratolo MD, et al
    Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.
    Lung Cancer. 2021;157:85-91.
    PubMed     Abstract available

  321. BASSE C, Daniel C, Livartowski A, Beaucaire-Danel S, et al
    Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
    Lung Cancer. 2021;157:79-84.
    PubMed     Abstract available

  322. CHINTALA NK, Restle D, Quach H, Saini J, et al
    CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
    Lung Cancer. 2021;157:48-59.
    PubMed     Abstract available

  323. CERESOLI GL, Ghirardelli P, Franceschini D, Scorsetti M, et al
    A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy".
    Lung Cancer. 2021;157:165-166.

  324. BARSKY AR, Yegya-Raman N, Katz SI, Simone CB 2nd, et al
    Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy.
    Lung Cancer. 2021;157:163-164.

    June 2021
  325. SU PL, Tsai JS, Yang SC, Wu YL, et al
    Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.
    Lung Cancer. 2021;158:137-145.
    PubMed     Abstract available

  326. WANG Z, Zhao J, Ma Z, Cui J, et al
    Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268].
    Lung Cancer. 2021 Jun 11. pii: S0169-5002(21)00426.

  327. BORG M, Wen SWC, Nederby L, Hansen TF, et al
    Performance of the EarlyCDT(R) Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Lung Cancer. 2021;158:85-90.
    PubMed     Abstract available

  328. QI M, Bian D, Zhang J, Zhu X, et al
    The modification of T description according to visceral pleural invasion and tumor size from 3.1cm to 4.0cm in non-small cell lung cancer: A retrospective analysis based on the SEER database.
    Lung Cancer. 2021;158:47-54.
    PubMed     Abstract available

  329. MELOSKY B, Wheatley-Price P, Juergens RA, Sacher A, et al
    The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Lung Cancer. 2021 Jun 5. pii: S0169-5002(21)00429.
    PubMed     Abstract available

  330. JOSHI K, Muhith A, Obeid M, Milner-Watts C, et al
    Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
    Lung Cancer. 2021;156:147-150.
    PubMed     Abstract available

  331. GACHECHILADZE M, Uberall I, Skanderova D, Matchavariani J, et al
    LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2021;156:129-135.
    PubMed     Abstract available

  332. LAROSE F, Quigley N, Lacasse Y, Martel S, et al
    Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
    Lung Cancer. 2021;156:151-156.
    PubMed     Abstract available

  333. PRIETO M, Chassagnon G, Lupo A, Charpentier MC, et al
    Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.
    Lung Cancer. 2021;156:117-121.
    PubMed     Abstract available

  334. SOLDATH P, Binderup T, Kjaer A, Federspiel B, et al
    Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients.
    Lung Cancer. 2021;156:109-116.
    PubMed     Abstract available

  335. LAU SCM, Poletes C, Le LW, Mackay KM, et al
    Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lung Cancer. 2021;156:76-81.
    PubMed     Abstract available

  336. NAKASUKA T, Ohashi K, Watanabe H, Kubo T, et al
    A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
    Lung Cancer. 2021;156:1-4.
    PubMed     Abstract available

    May 2021
  337. KIM HW, Kim JS, Lee SH
    Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Lung Cancer. 2021;158:107-114.
    PubMed     Abstract available

  338. GUO T, Zhu L, Li W, Lin R, et al
    Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
    Lung Cancer. 2021;161:94-97.
    PubMed     Abstract available

  339. SATO T, Shimada Y, Mimae T, Tsutani Y, et al
    The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.
    Lung Cancer. 2021;158:9-14.
    PubMed     Abstract available

  340. HE LN, Fu S, Zhang X, Hu Q, et al
    Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    Lung Cancer. 2021;158:1-8.
    PubMed     Abstract available

  341. LAVOLE A, Mazieres J, Schneider S, Brosseau S, et al
    Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
    Lung Cancer. 2021;158:146-150.
    PubMed     Abstract available

  342. DI STASIO GD, Travascio L, Colandrea M, Spaggiari L, et al
    Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
    Lung Cancer. 2021;158:40-46.
    PubMed     Abstract available

  343. GOKER E, Altwairgi A, Al-Omair A, Tfayli A, et al
    Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations.
    Lung Cancer. 2021;158:60-73.
    PubMed     Abstract available

  344. LIU R, Ota K, Iwama E, Yoneshima Y, et al
    Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
    Lung Cancer. 2021 May 25. pii: S0169-5002(21)00403.
    PubMed     Abstract available

  345. SPIRA AI, Tu H, Aggarwal S, Hsu H, et al
    A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Lung Cancer. 2021;159:1-9.
    PubMed     Abstract available

  346. OSTI MF, Agolli L, Valeriani M, Reverberi C, et al
    Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].
    Lung Cancer. 2021 May 21. pii: S0169-5002(21)00187.

  347. DUVERGE L, Bondiau PY, Claude L, Supiot S, et al
    Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
    Lung Cancer. 2021 May 15. pii: S0169-5002(21)00195.
    PubMed     Abstract available

  348. PROVENCIO M, Mazarico Gallego JM, Calles A, Antonanzas M, et al
    Lung cancer patients with COVID-19 in Spain: GRAVID study.
    Lung Cancer. 2021 May 14. pii: S0169-5002(21)00193.
    PubMed     Abstract available

  349. WISLEZ M, Domblides C, Greillier L, Mazieres J, et al
    Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00192.
    PubMed     Abstract available

  350. PILLERON S, Maringe C, Charvat H, Atkinson J, et al
    Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00194.
    PubMed     Abstract available

  351. ROGASCH JMM, Frost N, Bluemel S, Michaels L, et al
    FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
    Lung Cancer. 2021 May 7. pii: S0169-5002(21)00171.
    PubMed     Abstract available

  352. LEI H, Yang Y, Zhou W, Zhang M, et al
    Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
    Lung Cancer. 2021 May 5. pii: S0169-5002(21)00170.
    PubMed     Abstract available

  353. WANG LL, Yu H, Wang HY, Liu T, et al
    Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2021 May 3. pii: S0169-5002(21)00168.

    The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events.
    Lung Cancer. 2021;155:191-192.

  355. HALMOS B, Burke T, Kalyvas C, Vandormael K, et al
    Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
    Lung Cancer. 2021;155:175-182.
    PubMed     Abstract available

  356. SUMI T, Nakata H, Chiba H
    Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment.
    Lung Cancer. 2021;155:196-198.

  357. LUO Y, Wei J, Zhang J, Zeng L, et al
    Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
    Lung Cancer. 2021;155:170-174.
    PubMed     Abstract available

  358. NOORDHOF AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al
    Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Lung Cancer. 2021;155:163-169.
    PubMed     Abstract available

  359. VAN DE STADT EA, Yaqub M, Lammertsma AA, Poot AJ, et al
    Identifying advanced stage NSCLC patients who benefit from afatinib therapy using (18)F-afatinib PET/CT imaging.
    Lung Cancer. 2021;155:156-162.
    PubMed     Abstract available

  360. LV W, Wang Y, Zhou C, Yuan M, et al
    Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study.
    Lung Cancer. 2021;155:78-86.
    PubMed     Abstract available

  361. ZHAO D, Hou F, Li M, Qi Y, et al
    A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma.
    Lung Cancer. 2021;155:193-195.

  362. MORENO-RUIZ P, Corvigno S, Te Grootenhuis NC, La Fleur L, et al
    Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
    Lung Cancer. 2021;155:10-19.
    PubMed     Abstract available

  363. FOREST F, Casteillo F, Da Cruz V, Yvorel V, et al
    Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
    Lung Cancer. 2021;155:1-9.
    PubMed     Abstract available

  364. ARRIETA O, Salas AA, Cardona AF, Diaz-Garcia D, et al
    Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.
    Lung Cancer. 2021;155:183-190.
    PubMed     Abstract available

    April 2021
  365. DEBIEUVRE D, Juergens RA, Asselain B, Audigier-Valette C, et al
    Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Lung Cancer. 2021 Apr 30. pii: S0169-5002(21)00165.
    PubMed     Abstract available

  366. CHEN N, Li Q, Wang S, Xiong M, et al
    Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).
    Lung Cancer. 2021;156:82-90.
    PubMed     Abstract available

  367. NEWMAN NB, Osmundson EC
    Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.
    Lung Cancer. 2021 Apr 26. pii: S0169-5002(21)00161.
    PubMed     Abstract available

  368. FROESCH P, Mark M, Rothschild SI, Li Q, et al
    Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
    Lung Cancer. 2021;156:91-99.
    PubMed     Abstract available

  369. PALL G, Gautschi O
    Advances in the treatment of RET-fusion-positive lung cancer.
    Lung Cancer. 2021 Apr 24. pii: S0169-5002(21)00159.
    PubMed     Abstract available

  370. KUZDZAL J, Trybalski L, Hauer L, Cmiel A, et al
    Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study.
    Lung Cancer. 2021 Apr 22. pii: S0169-5002(21)00160.
    PubMed     Abstract available

  371. TAMMEMAGI MC, Darling GE, Schmidt H, Llovet D, et al
    Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Lung Cancer. 2021;156:31-40.
    PubMed     Abstract available

  372. ZHANG CC, Hou RP, Xia WY, Zeng WQ, et al
    Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study.
    Lung Cancer. 2021;156:100-108.
    PubMed     Abstract available

  373. HORIUCHI K, Sato T, Kuno T, Takagi H, et al
    Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021;156:59-67.
    PubMed     Abstract available

  374. BOGART JA, Wang X, Masters GA, Gao J, et al
    Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
    Lung Cancer. 2021;156:68-71.
    PubMed     Abstract available

  375. HSU CL, Tsai TH, Huang CK, Yang CY, et al
    Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
    Lung Cancer. 2021;156:50-58.
    PubMed     Abstract available

  376. VON DER THUSEN JH, Dumoulin DW, Maat APWM, Wolf J, et al
    ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype.
    Lung Cancer. 2021;156:72-75.
    PubMed     Abstract available

  377. MILLER HA, Yin X, Smith SA, Hu X, et al
    Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
    Lung Cancer. 2021;156:20-30.
    PubMed     Abstract available

  378. ITO S, Asahina H, Honjo O, Tanaka H, et al
    Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
    Lung Cancer. 2021;156:12-19.
    PubMed     Abstract available

  379. WATERHOUSE D, Lam J, Betts KA, Yin L, et al
    Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Lung Cancer. 2021;156:41-49.
    PubMed     Abstract available

  380. SCHREUDER A, Mets OM, Schaefer-Prokop CM, Jacobs C, et al
    Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
    Lung Cancer. 2021;156:5-11.
    PubMed     Abstract available

  381. VISSER MPJ, van Grimbergen I, Holters J, Barendregt WB, et al
    Performance insights of endobronchial ultrasonography (EBUS) and mediastinoscopy for mediastinal lymph node staging in lung cancer.
    Lung Cancer. 2021 Apr 7. pii: S0169-5002(21)00132.
    PubMed     Abstract available

  382. YANG L, Zhao W, Zhu H, Li X, et al
    PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;154:219-220.

  383. COSTA FA, Amano MT, Asprino PF, Pavlick DC, et al
    Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.
    Lung Cancer. 2021;154:146-150.
    PubMed     Abstract available

  384. VOLCKMAR AL, Christopoulos P, Kirchner M, Allgauer M, et al
    Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
    Lung Cancer. 2021;154:131-141.
    PubMed     Abstract available

  385. XIONG A, Li C, Xu J, Yang X, et al
    Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
    Lung Cancer. 2021;154:124-130.
    PubMed     Abstract available

  386. SHANG X, Li Z, Sun J, Zhao C, et al
    Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Lung Cancer. 2021;154:105-112.
    PubMed     Abstract available

  387. WANG YL, Wu ZZ, Zhang HR, Chen DS, et al
    Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Lung Cancer. 2021;154:216-218.

  388. ZHANG C, Wang H
    Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors.
    Lung Cancer. 2021;154:221-223.

  389. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Lung Cancer. 2021;154:92-98.
    PubMed     Abstract available

  390. ZHANG C, Wang H
    The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores.
    Lung Cancer. 2021;154:214-215.

  391. WEISSFERDT A, Pataer A, Swisher SG, Heymach JV, et al
    Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
    Lung Cancer. 2021;154:76-83.
    PubMed     Abstract available

  392. LI Z, Li F, Pan C, He Z, et al
    Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma.
    Lung Cancer. 2021;154:69-75.
    PubMed     Abstract available

  393. COLLAUD S, Alnajdawi Y, Stork T, Plones T, et al
    Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience.
    Lung Cancer. 2021;154:23-28.
    PubMed     Abstract available

  394. KATZ SI, Roshkovan L, Berger I, Friedberg JS, et al
    Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Lung Cancer. 2021;154:5-12.
    PubMed     Abstract available

  395. PATHIPATI MP, Yohannan TK, Tian L, Hornbacker K, et al
    Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.
    Lung Cancer. 2021;154:186-194.
    PubMed     Abstract available

    March 2021
  396. BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
    Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
    Lung Cancer. 2021;155:136-143.
    PubMed     Abstract available

  397. FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
    Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
    Lung Cancer. 2021;155:144-150.
    PubMed     Abstract available

  398. EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
    Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
    Lung Cancer. 2021;155:114-119.
    PubMed     Abstract available

  399. TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
    Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2021;155:120-126.
    PubMed     Abstract available

  400. PARK K, Chang GC, Curigliano G, Lim WT, et al
    Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Lung Cancer. 2021;155:127-135.
    PubMed     Abstract available

  401. MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
    Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Lung Cancer. 2021;155:151-155.
    PubMed     Abstract available

  402. BABA K, Yoshida T, Shiotsuka M, Kobayashi O, et al
    Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.
    Lung Cancer. 2021;153:182-183.

  403. ARAUJO-FILHO JAB, Chang J, Mayoral M, Plodkowski AJ, et al
    Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
    Lung Cancer. 2021;153:158-164.
    PubMed     Abstract available

  404. FUCHS V, Roisman L, Kian W, Daniel L, et al
    The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
    Lung Cancer. 2021;153:126-133.
    PubMed     Abstract available

  405. LI R, Jiang L, Zhou X, Lu Y, et al
    Pseudo-small cell transformation in EGFR-mutant adenocarcinoma.
    Lung Cancer. 2021;153:120-125.
    PubMed     Abstract available

  406. MASRORI P, Vaesen Bentein H, Raskin J, Montagna M, et al
    Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
    Lung Cancer. 2021;153:117-119.
    PubMed     Abstract available

  407. ZHAI X, Wu Q, Zeng Z, Suo J, et al
    OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:171-173.

  408. WANG B, Chen R, Wang C, Chen H, et al
    PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:176-178.

  409. REN P, Luo N, Qi Y, Wu Y, et al
    A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
    Lung Cancer. 2021;153:179-181.

  410. DEVEAUX AE, Allen TA, Al Abo M, Qin X, et al
    RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
    Lung Cancer. 2021;153:90-98.
    PubMed     Abstract available

  411. LIU Y, Gao GF, Minna JD, Williams NS, et al
    Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.
    Lung Cancer. 2021;153:73-80.
    PubMed     Abstract available

  412. ZHOU F, Huang Y, Cai W, Li J, et al
    The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Lung Cancer. 2021;153:66-72.
    PubMed     Abstract available

  413. AMEMIYA R, Miyoshi T, Aokage K, Suzuki J, et al
    Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Lung Cancer. 2021;153:56-65.
    PubMed     Abstract available

  414. CHIA PL, Parakh S, Russell P, Gan HK, et al
    Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
    Lung Cancer. 2021;153:35-41.
    PubMed     Abstract available

  415. SUZUKI J, Aokage K, Neri S, Sakai T, et al
    Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
    Lung Cancer. 2021;153:1-10.
    PubMed     Abstract available

  416. KUNIMASA K, Oka T, Hara S, Yamada N, et al
    Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
    Lung Cancer. 2021;153:186-192.
    PubMed     Abstract available

    February 2021
  417. LIU L, Bai H, Seery S, Li S, et al
    Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis.
    Lung Cancer. 2021;158:74-84.
    PubMed     Abstract available

  418. CAI C, Tang Y, Li Y, Chen Y, et al
    Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Lung Cancer. 2021;152:104-108.
    PubMed     Abstract available

  419. LI X, Liu J, Guo M, Cai H, et al
    NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
    Lung Cancer. 2021;152:202-204.

  420. LAZAREV S, Rosenzweig K, Samstein R, Salgado LR, et al
    Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.
    Lung Cancer. 2021;152:157-164.
    PubMed     Abstract available

  421. ZHAO G, Chen L, Xiao M, Yang S, et al
    Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Lung Cancer. 2021;152:189-192.

  422. MARCUSE F, Hochstenbag M, Hoeijmakers JGJ, Hamid MA, et al
    Subclinical myasthenia gravis in thymomas.
    Lung Cancer. 2021;152:143-148.
    PubMed     Abstract available

  423. HIROSE T, Ikegami M, Endo M, Matsumoto Y, et al
    Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Lung Cancer. 2021;152:135-142.
    PubMed     Abstract available

  424. LIANG P, Qi L, Guo T, You X, et al
    A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Lung Cancer. 2021;152:193-195.

  425. MA H, Zhang Q, Duan Q, Zhang Q, et al
    Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
    Lung Cancer. 2021;152:196-198.

  426. BLAKE-CERDA M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, et al
    Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Lung Cancer. 2021;152:119-126.
    PubMed     Abstract available

  427. GENDARME S, Matton L, Antoine M, Kerrou K, et al
    Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
    Lung Cancer. 2021;152:94-97.
    PubMed     Abstract available

  428. BERGER I, Simpson S, Friedberg JS, Culligan MJ, et al
    CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.
    Lung Cancer. 2021;152:34-38.
    PubMed     Abstract available

  429. CHAE M, Jeon JH, Chung JH, Lee SY, et al
    Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection.
    Lung Cancer. 2021;152:21-26.
    PubMed     Abstract available

  430. KWOK WC, Cheong TF, Chiang KY, Ho JCM, et al
    Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid.
    Lung Cancer. 2021;152:15-20.
    PubMed     Abstract available

  431. GHIRARDELLI P, Franceschini D, D'Aveni A, Dominici L, et al
    Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
    Lung Cancer. 2021;152:1-6.
    PubMed     Abstract available

    January 2021
  432. LI X, Zhang D, Li B, Zou B, et al
    Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Lung Cancer. 2021;151:39-43.
    PubMed     Abstract available

  433. FAIVRE-FINN C, Spigel DR, Senan S, Langer C, et al
    Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
    Lung Cancer. 2021;151:30-38.
    PubMed     Abstract available

  434. LI M, Tang Q, Chen S, Wang Y, et al
    A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Lung Cancer. 2021;151:98-100.

  435. BUIKHUISEN WA, Steinbusch LC, Kodach LL, Tesselaar MET, et al
    Risk of second primary malignancies among patients with carcinoid of the lung.
    Lung Cancer. 2021;151:5-7.
    PubMed     Abstract available

  436. XIONG L, Li X, Chen D, Li S, et al
    GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:104-105.

  437. TAKAHASHI T, Umeguchi H, Tateishi A, Yoshida T, et al
    Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
    Lung Cancer. 2021;151:1-4.
    PubMed     Abstract available

  438. BLONS H, Oudart JB, Merlio JP, Debieuvre D, et al
    PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
    Lung Cancer. 2021;151:69-75.
    PubMed     Abstract available

  439. WANG H, Shan Q, Guo J, Han X, et al
    PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Lung Cancer. 2021;151:76-83.
    PubMed     Abstract available

    May 2020
  440. SMUK G, Pajor G, Szuhai K, Morreau H, et al
    Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Lung Cancer. 2020;143:80-85.
    PubMed     Abstract available

  441. OKUNO T, Arakawa S, Yoshida T, Ohe Y, et al
    Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Lung Cancer. 2020;143:95-96.

  442. KNEUERTZ PJ, Carbone DP, D'Souza DM, Shilo K, et al
    Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Lung Cancer. 2020;143:60-66.
    PubMed     Abstract available

  443. ZHOU Y, Jiang W, Zeng L, Mi J, et al
    A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Lung Cancer. 2020;143:55-59.
    PubMed     Abstract available

  444. SHERMAN S, Rotem O, Shochat T, Zer A, et al
    Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Lung Cancer. 2020;143:40-46.
    PubMed     Abstract available

  445. TREJO BITTAR HE, Jerome JA, Hartman D, Pantanowitz L, et al
    Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
    Lung Cancer. 2020;143:12-18.
    PubMed     Abstract available

    April 2020
  446. MOODLEY S, Lian EY, Crupi MJF, Hyndman BD, et al
    RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.
    Lung Cancer. 2020;142:123-131.
    PubMed     Abstract available

  447. SALA L, Mancin M, Pastore A, Seminati D, et al
    Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
    Lung Cancer. 2020;142:120-122.
    PubMed     Abstract available

  448. CHEN HF, Wang WX, Xu CW, Huang LC, et al
    A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Lung Cancer. 2020;142:59-62.
    PubMed     Abstract available

  449. ZUCALI PA, Perrino M, De Vincenzo F, Giordano L, et al
    A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Lung Cancer. 2020;142:132-137.
    PubMed     Abstract available

  450. CHAN OSH, Lam KC, Li JYC, Choi FPT, et al
    ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
    Lung Cancer. 2020;142:41-46.
    PubMed     Abstract available

  451. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer(1).
    Lung Cancer. 2020;142:28-33.
    PubMed     Abstract available

  452. AN N, Leng X, Wang X, Sun Y, et al
    Survival comparison of Three histological subtypes of lung squamous cell carcinoma: A population-based propensity score matching analysis.
    Lung Cancer. 2020;142:13-19.
    PubMed     Abstract available

    March 2020
  453. ITO M, Miyata Y, Tsutani Y, Ito H, et al
    Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Lung Cancer. 2020;141:107-113.
    PubMed     Abstract available

  454. GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
    Cytology for PD-L1 testing: A systematic review.
    Lung Cancer. 2020;141:101-106.
    PubMed     Abstract available

  455. LI C, Shen Y, Hu F, Chu T, et al
    Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
    Lung Cancer. 2020;141:72-77.
    PubMed     Abstract available

  456. ZHAO J, Lin G, Zhuo M, Fan Z, et al
    Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
    Lung Cancer. 2020;141:114-118.
    PubMed     Abstract available

    February 2020
  457. WANG F, Qin J, Xie F, Wu Q, et al
    Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Lung Cancer. 2020;140:118-120.

  458. LAM WS, Creaney J, Chen FK, Chin WL, et al
    A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lung Cancer. 2020;140:87-92.
    PubMed     Abstract available

  459. WU H, Dong S, Li X, Shi L, et al
    Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Lung Cancer. 2020;140:80-86.
    PubMed     Abstract available

  460. REALE ML, Chiari R, Tiseo M, Vitiello F, et al
    Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Lung Cancer. 2020;140:71-79.
    PubMed     Abstract available

  461. BALDINI E, Lunghi A, Cortesi E, Turci D, et al
    Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Lung Cancer. 2020;140:59-64.
    PubMed     Abstract available

  462. GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
    Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Lung Cancer. 2020;140:42-45.
    PubMed     Abstract available

  463. SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
    Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Lung Cancer. 2020;140:35-41.
    PubMed     Abstract available

  464. EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
    Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Lung Cancer. 2020;140:116-117.

  465. SHOJI S, Watanabe S, Takamura K, Umezu H, et al
    First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
    Lung Cancer. 2020;140:113-115.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.